1,100 results

#100832-AAV1

Ready-to-use AAV1 particles produced from pAAV.hSyn.CaMPARI.WPRE.SV40 (#100832). In addition to the viral particles, you will also receive purified pAAV.hSyn.CaMPARI.WPRE.SV40 plasmid DNA. Synapsin-driven, photoconvertible (irreversible green-to-red) calcium integrator. These AAV preparations are suitable purity for injection into animals.

Loren Looger, Eric Schreiter

Fosque et al Science. 2015 Feb 13;347(6223):755-60. d

April 6, 2018

Academic Institutions and Nonprofits only

#99130-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-mDlx-NLS-mRuby2 (#99130). In addition to the viral particles, you will also receive purified pAAV-mDlx-NLS-mRuby2 plasmid DNA. mDlx-driven NLS-mRuby2 expression. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Chan et al Nat Neurosci. 2017 Aug;20(8):1172-1179.

Sept. 18, 2019

Academic Institutions and Nonprofits only

#157970-AAV.A01.T

Ready-to-use AAV2 in TMN200 particles produced from pTR-UF11 (#157970). In addition to the viral particles, you will also receive purified pTR-UF11 plasmid DNA. 'Humanized' GFP driven by Chimeric CMV/Chicken Beta Actin promoter

Sergei Zolotukhin

Burger et al Mol Ther. 2004 Aug;10(2):302-17. doi: 10

Dec. 21, 2020

Academic Institutions and Nonprofits only

#153286-AAV2

Ready-to-use AAV2 particles produced from pAAV-hsyn-GRAB_Ado1.0med (#153286). In addition to the viral particles, you will also receive purified pAAV-hsyn-GRAB_Ado1.0med plasmid DNA. Synapsin-driven expression of GRAB_Ado1.0med adenosine sensor in neurons. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Wu et al Proc Natl Acad Sci U S A. 2023 Apr 4;120

Nov. 13, 2025

Academic Institutions and Nonprofits only

#100832-AAV9

Ready-to-use AAV9 particles produced from pAAV.hSyn.CaMPARI.WPRE.SV40 (#100832). In addition to the viral particles, you will also receive purified pAAV.hSyn.CaMPARI.WPRE.SV40 plasmid DNA. Synapsin-driven, photoconvertible (irreversible green-to-red) calcium integrator. These AAV preparations are suitable purity for injection into animals.

Loren Looger, Eric Schreiter

Fosque et al Science. 2015 Feb 13;347(6223):755-60. d

April 17, 2018

Academic Institutions and Nonprofits only

#35512-AAV2

Ready-to-use AAV2 particles produced from pAAV-CaMKIIa-hChR2(E123T/T159C)-mCherry (#35512). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hChR2(E123T/T159C)-mCherry plasmid DNA. CaMKIIa-driven, humanized channelrhodopsin E123T/T159C mutant fused to mCherry for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Mattis et al Nat Methods. 2011 Dec 18;9(2):159-72. do

Nov. 13, 2025

Academic Institutions and Nonprofits only

#105321-AAV1

Ready-to-use AAV1 particles produced from pGP-AAV-syn-jGCaMP7c variant 1513-WPRE (#105321). In addition to the viral particles, you will also receive purified pGP-AAV-syn-jGCaMP7c variant 1513-WPRE plasmid DNA. Synapsin-driven jGCaMP7c expression. jGCaMP7c exhibits high contrast between peak fluorescence and resting fluorescence. It is useful for activity imaging of large populations of densely-labeled neurons because background fluorescence from inactive neurons is reduced. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al Nat Methods. 2019 Jul;16(7):649-657. doi

July 12, 2019

Academic Institutions and Nonprofits only

#214862-PHPeB

Ready-to-use AAV PHP.eB particles produced from AiP14825: pAAV-AiE0441h_3xC2-minBG-iCre(R297T)-BGHpA (Alias: CN4825) (#214862). In addition to the viral particles, you will also receive purified AiP14825: pAAV-AiE0441h_3xC2-minBG-iCre(R297T)-BGHpA (Alias: CN4825) plasmid DNA. minBG-driven expression of iCre(R297T) in striatal medium spiny neurons. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Jonathan Ting

Hunker et al Neuron. 2025 May 21;113(10):1507-1524.e1

Nov. 13, 2024

Academic Institutions and Nonprofits only

#135633-AAV1

Ready-to-use AAV1 particles produced from pAAV-S5E2-C1V1-eYFP (#135633). In addition to the viral particles, you will also receive purified pAAV-S5E2-C1V1-eYFP plasmid DNA. Expression of red-shifted opsin C1V1 fused to EYFP under the control of the E2 regulatory element. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Aug. 27, 2021

Academic Institutions and Nonprofits only

#69571-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-C-CreintG (#69571). In addition to the viral particles, you will also receive purified pAAV-EF1a-C-CreintG plasmid DNA. EF1a-driven expression of optimized C-terminal component of Cre recombinase dependent on GFP (Cre-DOG OPT); to be coinjected with pAAV-EF1a-N-CretrcintG (Addgene catalog# 69570) and GFP (or for use with transgenic GFP animals). These AAV preparations are suitable purity for injection into animals.

Connie Cepko

Tang et al Nat Neurosci. 2015 Sep;18(9):1334-41. do

Feb. 19, 2020

Academic Institutions and Nonprofits only